XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Operating expenses      
Research and development $ (51,857,545) $ (13,279,780) $ (8,358,043)
Selling, general and administrative (32,855,959) (4,898,942) (1,233,876)
New Warrants expenses (104,776,230) 0 0
Loss from operations (189,489,734) (18,178,722) (9,591,919)
Change in fair value of derivative liabilities 9,547,500 0 0
Financial and foreign exchange gain/(loss), net 6,844,856 (77,147) (34,023)
Loss before income taxes (173,097,378) (18,255,869) (9,625,942)
Income tax expense (932,980) 0 0
Net loss $ (174,030,358) $ (18,255,869) $ (9,625,942)
Net loss per share basic $ (0.68) $ (0.08) $ (0.04)
Net loss per share diluted $ (0.68) $ (0.08) $ (0.04)
Weighted-average number of shares outstanding – basic 254,131,038 220,000,000 220,000,000
Weighted-average number of shares outstanding – diluted 254,131,038 220,000,000 220,000,000